Skip to content
★ Sign in to follow
PegBio Co., Ltd. - B - H Shares logo

PegBio Co., Ltd. - B - H Shares Stock: price and insider trades · Hong Kong

HK·Mcap HK$1.4BHealth Care

No insider purchase over the last 90 days. The latest, by XU Michael Min, was filed 02 Jul 2026.

PegBio Co., Ltd. - B - H Shares: what insiders have been doing

PegBio Co., Ltd. - B - H Shares belongs to the Health Care sector. Filings by its managers are published through HKEX. The last twelve months, up to 23 October 2026, brought 5 filings signed by 4 insiders.

Purchases and sales both appear in the filings: 1 purchase (1 insider) and 1 sale (1 insider). The totals do not cover 2 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive.

With 5 filings in twelve months, the company is more active than the median of 4 filings across the 1,315 companies we follow on the same exchange. The full history, which starts in 2026, counts 1 purchase against 1 sale.

The most recent open-market purchase was published on 2 July 2026, 129 days ago. Between a trade and the moment it shows up on HKEX, the median delay is 7 days. Until a filing is published, the market cannot know about the trade.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.

Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
n/a
1 ops. · all time

Who traded when

BuySale
XU Michael Min1 buy1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$3.70
Analyst consensus
·
Income statement
EBITDA-HK$202M
Net income-HK$208.4M0.0% margin
Valuation
P/Book4.6x
Balance sheet & cash
Market capHK$1.4B
Total debtHK$93.6M
Free Cash Flow-HK$155.6M
Debt / Equity57%
Profitability & ownership
ROE-125.6%
ROA-44.5%
% insiders32.6%
% institutions5.9%
Last declaration on 2 July 2026
Declarations5 total
  • ●
    DirectorExecutives
    11HKEX
    6,810,871 sharesShareXHKGHKEX:DA20260701E00011
  • ▼
    DirectorExecutives
    11HKEX
    40,657,312 sharesShareXHKGHKEX:DA20260701E00007
  • ●
    DirectorExecutives
    13HKEX
    29,175,230 sharesShareXHKGHKEX:DA20260701E00008
  • ●
    DirectorExecutives
    13HKEX
    6,268,463 sharesShareXHKGHKEX:DA20260701E00009
  • ▲
    DirectorExecutives
    0HKEX
    40,657,312 sharesShareXHKGHKEX:DA20260701E00006
    Canonical exit: 23 Sept 2026 (T+90)

5 of 5 declarations

About PegBio Co., Ltd. - B - H Shares

PegBio Co., Ltd. is a company focused on the development of biopharmaceutical products. It specializes in the research and commercialization of innovative treatments for various diseases.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations